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Abstract
Background: Microsatellite instability, the main genetic element in HNPCC syndrome, is associated with a number of cancers,
including ovarian epithelial carcinomas. These cancers have distinct characteristics compared to non-MSI related ones.
Objectives: The present study aims at determining the prevalence of microsatellite instability in ovarian carcinomas and their
associated factors in Iranian patients.
Methods: Paraffin-embedded blocks, belonging to 37 patients with definite diagnosis of ovarian epithelial cancers, were retrieved
from the archives. After DNA extraction from tumor tissue and PCR reaction, the results were assessed in accordance with melting
curve analysis. Subsequently, the relationship among microsatellite status and tumor histology, grade, stage, and size were investi-
gated statistically.
Results: The predominant histological type was serous histology. Four out of 37 carcinomas were microsatellite unstable (10.8%)
and only 1 was MSI-high type (2.1%). The MSI was more frequent among younger patients with unilateral, non-serous histology, non-
high grade, and stage I tumors without omental involvement. After statistical analysis, the only significant relationship was found
between histological type (non-serous) and microsatellite status.
Conclusions: Microsatellite stable and unstable ovarian cancers may have different associations with various factors in a sample of
Iranian women. The identification of these characteristics may help narrow down indications to test this prognostic and predictive
genetic error.
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1. Background
The DNA mismatch repair (MMR) system is responsible
for correcting genetic errors in the coding and non-coding
DNA regions throughout the genome (1). However, when
the MMR system is defected, these errors could pass to the
next generation of cells. MMR system deficiency may lead
to genetically uncorrected cellular proliferation and, con-
sequently, to the development of a number of neoplasms
in the human body (2). Microsatellites are small, repetitive
sequences of DNA, consisting of 1- to 6-base pairs that are
distributed throughout the human genome. When the de-
fined number of each microsatellite is altered, through in-
sertion or deletion of 1 or more base pairs, it is called mi-
crosatellite instability (3). Microsatellite instability (MSI) is
a reflection of the defects in a DNA mismatch repair system.
The most well-established link between MSI and ma-
lignant neoplasm has been reported in colorectal can-
cers, where 15% to 20% of sporadic tumors are MSI related
(4). Another less studied, yet important neoplasm that
has been associated with MSI is ovarian epithelial cancer,
which is the fifth most common cancer among women
worldwide. Ovarian cancers are commonly diagnosed at
later stages, and are among the most deadly gynecological
malignancies in women (5). Limited studies in our country
have investigated the etiology and prognosis of this type
of malignancy. Therefore, in ovarian carcinomas, molecu-
lar and genetic prognostic and predictive factors, includ-
ing DNA mismatch repair system and its reflection, MSI, are
worth investigating.
Ovarian cancers that are associated with MSI, like other
organs with similar genetically based errors, may have dis-
tinct characteristics in terms of age at presentation, mor-
Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in
noncommercial usages, provided the original work is properly cited.
Shahsiah R et al.
tality rate, and response to standard chemotherapeutical
regimens.
MMR-related colon cancers have better prognosis com-
pared to those without this genetic defect (3). The same
phenomenon may be true with ovarian cancers. Classic
platinum-based chemotherapies are the mainstay in the
treatment of both early and advanced carcinomas. Nev-
ertheless, some studies have shown, although not defini-
tively, that these particular types of cancer may show some
sort of resistance to routine chemotherapy regimens, in-
cluding platinum (cisplatin and carboplatin) and taxane
(paclitaxel) (6). Hence, the detection of the underlying
MMR system defects in ovarian epithelial neoplasms may
lead clinicians to select more efficacious treatment strate-
gies, alongside better imagination of the natural course of
the disease.
To date, no study has been conducted in Iranian, and
even among Middle Eastern populations, to determine the
prevalence and associated factors of microsatellite insta-
bility in ovarian epithelial carcinomas. Given the different
outcomes described for these types of tumors, this study
could provide a clearer picture of ovarian epithelial can-
cers’ profile in the Iranian population.
2. Methods
2.1. Preparation of Samples
In this study, the specimens with previously con-
firmed diagnosis of ovarian epithelial carcinoma, from
2010 to 2014, were retrieved from the archives and pre-
pared for molecular studies. The patients had given in-
formed consents at the time of admission in order that
their specimens in pathology laboratory would be avail-
able for research purposes in future. Institutional review
board and ethics committee confirmed the study design.
First, authors reviewed all slides and the original paraffin-
embedded tissue blocks were sent to the molecular pathol-
ogy laboratory. The samples were prepared as three 5-
micrometer thick slices from tumor tissue. The first 2 slices
were sent for DNA extraction and the third was stained
with H&E to confirm the presence of tumor in the sliced
areas. A sample would be excluded if the DNA extraction
failed or if there was no tumor cell present in the light mi-
croscopic evaluation. In order to prevent contamination
of samples, each slice was cut by a new blade and, then, the
slices were transferred to 1.5-mL Eppendorf tubes by dis-
posable applicators. Subsequently, paraffin was removed
by adding xylene and the samples were washed with pure
ethanol. In the next step, tissue lysis buffer and proteinase
K were added to microtubes and were placed at a temper-
ature of 55°C. After complete dissolution of all the tissue
fragments, a binding buffer, isopropanol, and an inhibitor-
removal buffer were added and centrifuged briefly. Fi-
nally, the tumor DNA was purified, using DNA extraction
kit (Roche diagnostics GmbH, Mannheim, Germany). The
extracted tumor DNA was diluted to 1:10 by adding elution
buffer.
2.2. Microsatellite Analysis
Forward and reverse primers for amplification of se-
quences NR27, BAT26, BAT25 NR24, and NR21 were ordered
at Macrogen (Geum Chun-Gu, Seoul, Korea) with their pre-
viously defined sequences (7). The PCR for target sequences
was performed in 20 µL reaction containing 10 µL of 2x
SYBER premix ex Taq master mix (Takara Bio, Ostu, Shiga,
Japan), 1µL of forward and reverse primers with concentra-
tion of 10 PM/µL, and about 50 ng extracted tumor DNA. Fi-
nally, the PCR reaction was performed in light cycler Nano
machine (Roche diagnostics GmbH, Mannheim, Germany)
with PCR condition, being initial denaturation at 94°C for
0.5 minutes; then, 45 two-step cycles as follows: 95°C for
10 seconds; and 60°C for 30 seconds. Finally, a 5-minutes
terminal extension was performed at 72°C, followed by a
melting analysis of the PCR product. The melting graphs
were assessed, and if acceptable, the samples were sent to
Macrogen (Geum chun-gu, Seoul, Korea) for capillary elec-
trophoresis. The results of electrophoresis were analyzed,
using peck scanner software version 1.0 (applied biosys-
tems, CA, USA). Instability in 2 or more markers was con-
sidered MSI-H, and instability in 1 marker was considered
MSI-L.
2.3. Immunohistochemistry
IHC staining was carried out on the MSI-H specimen
with anti-MLH1, MSH2, MSH6, and PMS2 antibodies (Dako,
Glostrup, Denmark).
2.4. Statistical Analysis
To analyze the correlations of microsatellite instabil-
ity with histological grade, FIGO stage, tumor laterality,
and omental involvement among ovarian carcinomas, Chi-
squared tests were carried out. P value < 0.05 was regarded
as statistically significant.
3. Results
In this study, the specimens belonging to 37 malignant
ovarian epithelial tumors were assessed for microsatellite
instability. The mean age of the patients was 45.13± 9.50.
The mean size of the tumors was 11.40 ± 5.96 cm. Nine-
teen tumors (51.4%) were unilateral. Among various his-
tological types, serous adenocarcinoma was the predom-
inant type, with 54.1% of all carcinomas, while others were
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endometrioid with 21.6%, clear-cell with 13.5%, and muci-
nous with 10.8%. Based on the world health organization
(WHO) classification for histological grading, 61.1% were
high grade, while 16.7% and 22.2% were low and intermedi-
ate grade, respectively. According to the FIGO staging sys-
tem, 47.2%, 5.6%, and 47.2% of the tumors were stage I, II,
and III, respectively. About 43% of the tumors were associ-
ated with omental involvement.
Of our specimens, only 4 out of 37 (10.8) were mi-
crosatellite unstable (CI95% = 2.7 - 21.6). The rate of MSI-H
and MSI-L were 2.7% (1.37) and 8.1% (3.37), respectively. The
only tumor with MSI-H, in which capillary electrophore-
sis graph shows instability in BAT26, NR24, NR27 (Figure
1), was a unilateral, 9 cm, Grade II endometrioid adeno-
carcinoma, with FIGO stage IIB, and without omental in-
volvement. Shown in Table 1, the rate of microsatellite in-
stability is higher among patients under 45, with larger
than 10 cm, and unilateral tumors, compared to older
women, who had smaller and bilateral tumors. One of the
major endpoints of this study was the assessment of the
relationship between MSI status with tumor histological
type, grade, and FIGO stage. Our study showed that mi-
crosatellite instability was more prevalent in non-serous,
low-intermediate grade, and stage I neoplasms. Also, the
MSI was more pronounced in cases with no omental in-
volvement. According to a significance level of 0.05, the
histological type was the only parameter having a signifi-
cant relationship with the MSI tumors.
The characteristics of microsatellite unstable ovarian
epithelial cancers have been depicted in Table 2, where
NR21 and BAT26 loci were predominant mutations, each
found in the 2 cases.
Nuclear immunoreactivity for hMLH1, hMSH2, hMSH6,
and PMS2 proteins was performed on the only MSI-H tu-
mor of our specimens. In addition, hMLH1 and PMS2
showed positive nuclear reaction, whereas hMSH2 and
hMSH6 showed a negative result that is consistent with the
molecular method (Figure 2).
4. Discussion
Generally, immunohistochemistry and molecular ge-
netic studies have been used to assess MMR proteins or
their coding genes. According to the literature, the MSI de-
tection method has been the more cost-effective and accu-
rate, along with the fact that it is suitable in clinical set-
tings (8). Following an NCI workshop in 1977, Bethesda
markers were introduced for the detection of MSI in colon
cancer. Despite the well-known efficacy in colon carcinoma
of Lynch syndrome, it remained uncertain whether these
markers were the best option for assessing MMR-related
ovarian cancers (4). We used 5 mononucleotide markers
included in the MSI analysis system, of which BAT25 and
BAT26 are shared with the Bethesda panel. Recent studies
have shown that the use of pentaplex panel of mononu-
cleotide markers show superior results in terms of sensitiv-
ity and specificity compared to NCI panel. Moreover, there
is no need for simultaneous normal DNA matching be-
cause of the quasimonomorphic nature of pentaplex panel
(9-12).
In our study, about 11% (CI95%: 2.7 - 21.6) of specimens
were positive for MSI, of which, 3 were MSI-L and only 1
was MSI-H. Moreover, in other studies among non-selected
cases of ovarian cancers, between 0% to 37% have been MSI-
H positive (13). The wide range was due to differences in
study design, number, and type of detector markers and
the criteria for the definition of MSI-H (14, 15). However, in
the studies using Bethesda panel markers or MSI analysis
system, the rate of MMR system defects has been reported
at about 10% (CI95% = 6 - 14) in ovarian epithelial cancers
(16-18). Therefore, our results are consistent with previous
findings regarding the overall rate of MSI in all histological
types.
In previous reports, the overall rate of BAT25 and BAT26
positivity was 6.7% and 4.8%, respectively, using different
MSI panels (16). Similarly, 5.4% of our samples were insta-
ble for BAT26, while none showed instability for BAT25.
In the present study, the prevalence of MSI was sig-
nificantly higher among non-serous carcinomas, while all
serous tumors were microsatellite stable. The only MSI-H
case was an endometrioid adenocarcinoma (12.5% of this
type). Other studies also pointed out that non-serous ma-
lignant ovarian tumors were more likely to be MSI positive
(13). This finding is considered important because serous
histology is the dominant type in all ovarian carcinomas
(more than 50% in our study).
This higher rate of microsatellite instability among
non-serous tumors can be explained by the fact that such
ovarian tumors, endometrioid and mucinous in particu-
lar, may be metastatic sites of undiagnosed primary en-
dometrial or colon cancers, and we know that the MMR de-
fect is responsible for a considerable fraction of these car-
cinomas (14).
Immunohistochemical staining was performed on the
only case that showed MSI-H in molecular method. This
case showed negative reaction for MSH2 and MSH6, while
it was positive for MLH1 and PMS2 that is consistent with a
deficiency in the MMR system. Other studies have shown
a frequency of about 6.4% loss in MLH1 or MSH2 in ovar-
ian carcinomas (16). Meanwhile, the loss of MSH6 is more
common in certain variants of ovarian carcinomas, such as
clear-cell, endometrioid, and mucinous types (19).
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Figure 1. MSI-H Tumor: Electrophoresis Shows Instability in BAT26, NR24, and NR27
Table 1. The Relationship of MS Status with Grade, Stage, etc
Characteristic Microsatellite Instability, N (%) Microsatellite Stable, N (%) P Value
High Low Total
Age group 0.99
< 45 Years 1 (6.2%) 1 (6.2%) 2 (12.5%) 14 (87.5%)
> or = 45 Years - 2 (9.5%) 2 (9.5%) 19 (90.5%)
Size 0.6
< 10 cm 1 (5.9%) - 1 (5.9%) 16 (94.1%)
> or = 10 cm - 3 (15.0%) 3 (15.0%) 17 (85.0%)
Side 0.1
Unilateral 1 (5.3%) 3 (15.8%) 4 (21.1%) 15 (78.9%)
Bilateral - - 0 (0%) 18 (100%)
Histologic type 0.036
Serous - - 0 (0%) 20 (100%)
Non-serous 1 (5.9%) 3 (17.6%) 4 (23.5%) 13 (76.5%)
Histologic grading 0.63
Low to moderate 1 (7.1%) 1 (7.1%) 2 (14.3%) 12 (85.7%)
High - 2 (9.1%) 2 (9.1%) 20 (90.9%)
FIGO staging 0.32
I - 3 (17.6%) 3 (17.6%) 14 (82.4%)
II or III 1 (5.3%) - 1 (5.3%) 18 (94.7%)
Omentum status 0.11
Involved - - 0 (0%) 16 (100%)
Free 1 (5.0%) 3 (15.0%) 4 (20.0%) 16 (80.0%)
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Table 2. Characteristics of MS Instable Ovarian Cancers in Our Study
Age Side Size (cm) Histology Grade FIGO Stage Omentum Mutant Mono/Dinucleotide MS Status
42 Unilateral 13 Mucinous Low IA Free NR21 MSI-L
51 Unilateral 13 Clear Cell High IA Free BAT26 MSI-L
48 Unilateral 11 Clear Cell High IA Free NR21 MSI-L
35 Unilateral 9 Endometrioid Moderate IIB Free BAT26, NR24, NR27 MSI-H
Figure 2. IHC study for hMLH1, hMSH2, hMSH6, and PMS2
4.1. Conclusions
In this study, we used microsatellite assay to find the
genomic defects in DNA mismatch repair system. We could
say that the DNA mismatch repair system defects, to which
a small but critical fraction of ovarian epithelial carcino-
mas is attributable, deserve routine investigation. The lat-
ter is especially important in the case of non-serous ovar-
ian epithelial cancers. Pathologists should be aware of the
importance of reporting MSI as indicated, because it may
help define the best treatment strategy for MMR defected
cases.
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